Yaomingkant and AstraZeneca seize the market of rheumatoid arthritis in China

With the saturation of European and American pharmaceutical market, more and more biomedical giants begin to focus on the emerging market represented by China Novartis, Pfizer and other biomedical giants have already made their own layout in China There is an old saying in China that a strong dragon does not oppress a snake The best way to quickly enter this huge market is to cooperate with local Chinese biomedical companies, which is also the strategy of pharmaceutical giant AstraZeneca Recently, Wuxi Pharmaceutical Co., Ltd and medlmmune, a subsidiary of AstraZeneca, announced the timetable for the listing application of medi5117, a monoclonal antibody for rheumatoid arthritis, jointly developed by the two companies in China Medi5117 is an IL-7 monoclonal antibody designed by AstraZeneca for the Chinese market Both Wuxi apptec and medlmune have equal rights to the drug However, after China's CFDA approves the listing of medi5117, medlmune will have the priority to acquire shares in Wuxi apptec At present, both parties have submitted the application for listing of the drug to CFDA in December last year, and CFDA is expected to make a final decision by the end of this year As one of the largest cro enterprises in China, Wuxi apptec also hopes to seize this rare opportunity to expand its influence at home and abroad In recent years, the company is no longer satisfied with a single cro business, but chooses to work in the Chinese pharmaceutical market Based on the vast Chinese market, Wuxi apptec hopes to build itself into the preferred partner for all multinational pharmaceutical companies to enter the Chinese market! This cooperation with AstraZeneca undoubtedly brings Wuxi apptec a step closer to realizing this wish Meanwhile, Wuxi apptec's revenue in 2015 is expected to be between $790 million and $800 million, an increase of 18% over 2014 In order to achieve this goal, Wuxi apptec plans to spend 200 million US dollars on capital operation this year, double the scale of last year, including expanding the company's pharmaceutical production facilities and expanding the company's genomics business Detailed English report: partners Wuxi PharmaTech ($Wx) and AstraZeneca's ($Azn) MedImmune are on schedule with a rheumatoid arthritis treating anomaly designed for the Chinese market, as the country's regulators have accepted their application The injection, medi5117, is an interleukin-7 antibody designed to tamp down the inflammation at the heart of autoimmune diseases like arthritis The pair are developing the drug through a joint venture launched in 2012, maintaining equal ownership until the drug reaches the market, at which point AZ would have the option to buy out its partner The JV submitted MEDI5117 to the Chinese FDA in December, and, with the application's acceptance, WuXi and MedImmune expect to get a final decision this year AstraZeneca cut the cord on an osteoarthritic pain program for MEDI5117 last year but preserved the antibody's Chinese ambitions, relying on WuXi to handle development and manufacturing MEDI5117 presents a significant bit of potential revenue for the fast-growing CRO, which has augmented its traditio nal offerings with a few risk-sharing drug development deals WuXi's long-stated goal is to become the go-to partner for any drugmaker looking to break into the Chinese market, and its relatio nship with AstraZeneca could light the way for more collaborations, CEO Ge Li said "This initiative showcases WuXi's capabilities as a gateway for developing novel biologics in China," Li said in a statement Meanwhile, the CRO is forecasting 2015 revenue between $790 million and $800 million, good for 18% annual growth at midpoint To get there, WuXi is planning to spend up to $200 million on capital projects, nearly double last year's budget, building new manufacturing outposts in China and expanding the company's genomics heft with new lab capacity